A YIDD Mutation in a Case of Recurrent Hepatitis B after Liver Transplantation Induced by an S-escape Mutant
0
조회
0
다운로드
0
인용
0
참고문헌
초록
47-year-old woman underwent orthotopic liver transplantation (OLT) for hepatitis B virus (HBV)-related end-stage liver cirrhosis. The patient received hepatitis B immunoglobulin prophylaxis after OLT. Despite the protective level of the serum anti-hepatitis-B surface antibody, HBV recurred at 22 months post-OLT and induced subacute hepatic failure. The pre-OLT HBV genome contained a complex mutation pattern in overlapping frame regions of the surface (S) and polymerase (P) genes, which is the same mutation pattern as seen in post-OLT HBV DNA. G145R and K141R mutations in the “a” determinant were detected only in the post-OLT sample. Clevudine (30 mg once daily) was administered for recurrent hepatitis B. Hepatitis B was reactivated with a flare-up, and a M204I mutation (YIDD mutant type) appeared with a higher viral load at 9 months after clevudine treatment. We report here a case of a YIDD mutation that developed in recurrent hepatitis B after OLT induced by an S-escape mutant.
Abstract
47-year-old woman underwent orthotopic liver transplantation (OLT) for hepatitis B virus (HBV)-related end-stage liver cirrhosis. The patient received hepatitis B immunoglobulin prophylaxis after OLT. Despite the protective level of the serum anti-hepatitis-B surface antibody, HBV recurred at 22 months post-OLT and induced subacute hepatic failure. The pre-OLT HBV genome contained a complex mutation pattern in overlapping frame regions of the surface (S) and polymerase (P) genes, which is the same mutation pattern as seen in post-OLT HBV DNA. G145R and K141R mutations in the “a” determinant were detected only in the post-OLT sample. Clevudine (30 mg once daily) was administered for recurrent hepatitis B. Hepatitis B was reactivated with a flare-up, and a M204I mutation (YIDD mutant type) appeared with a higher viral load at 9 months after clevudine treatment. We report here a case of a YIDD mutation that developed in recurrent hepatitis B after OLT induced by an S-escape mutant.
참고문헌 (25)
- Villamil FG, "Hepatitis B: progress in the last 15 years", Liver Transpl, 8(10 suppl 1), pp.S59~S66 (2002)
- Papatheodoridis GV, "Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era", Am J Transplant, 3, pp.250~258 (2003)
- Al Faraidy K, "Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine", Transplantation, 64, pp.926~928 (1997)
- Samuel D, "Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients", Lancet, 337, pp.813~815 (1991)
- Grellier L, "Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis", J Viral Hepat, 4(Suppl 1), pp.111~116 (1997)
- Pruett TL, "Hepatitis B immune globulin: the US experience", Clin Transplant, 14(Suppl 2), pp.7~13 (2000)
- Perrillo RP, "A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B", Hepatology, 33, pp.424~432 (2001)
- Protzer U, "Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation", J Med Virol, 50, pp.135~144 (1996)
- Santantonio T, "Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis", Hepatogastroenterology, 46, pp.1848~1854 (1999)
- Cooreman MP, "Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen", J Biomed Sci, 8, pp.237~247 (2001)
- Tabor E, "Infections by hepatitis B surface antigen gene mutants in Europe and North America", J Med Virol, 78(Suppl 1), pp.S43~S47 (2006)
- Yoshida EM, "De novo acute hepatitis B infection in a previously vaccinated liver transplant recipient due to a strain of HBV with a Met 133 Thr mutation in the "a" determinant", Liver, 20, pp.411~414 (2000)
- Kim KH, "Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy", J Med Virol, 71, pp.367~375 (2003)
- Protzer-Knolle U, "Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation", Hepatology, 27, pp.254~263 (1998)
- Ghany MG, "Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis", Hepatology, 27, pp.213~222 (1998)
- Carman WF, "Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis", Hepatology, 24, pp.489~493 (1996)
- Trautwein C, "Hepatitis B virus mutations in the pre-S genome before and after liver transplantation", Hepatology, 24, pp.482~488 (1996)
- Bock CT, "Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation", Gastroenterology, 122, pp.264~273 (2002)
- Rodriguez-Frias F, "Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation", Liver, 19, pp.177~182 (1999)
- Torre F, "Evolution of wild-type and precore mutant HBV infection after liver transplantation", J Med Virol, 59, pp.5~13 (1999)
- Chen JW, "Unique pattern of fibrosing cholestatic hepatitis after liver transplantation", Hepatobiliary Pancreat Dis Int, 1, pp.33~34 (2002)
- Thung SN, "Histologic findings in recurrent HBV", Liver Transpl, 12(11 Suppl 2), pp.S50~S53 (2006)
- Booth JC, "Fibrosing cholestatic hepatitis in a renal transplant recipient associated with the hepatitis B virus precore mutant", J Hepatol, 22, pp.500~503 (1995)
- Fang JW, "Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant", Gastroenterology, 105, pp.901~904 (1993)
- Lo CM, "Fibrosing cholestatic hepatitis secondary to precore", core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin, 2004, pp.10, 557~563